CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01044576
NCT01044576N/ACompleted
CompareCT.gov

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis Opening the Window of Therapeutic Opportunity

Imperial College London·observational·Posted Jan 8, 2010·Updated Mar 8, 2021

In Brief

An observational study for Relapsing-remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The primary goal of the research cohort is to facilitate patient access to clinical trials testing new therapeutic interventions, or access to second- line treatments. Secondary objectives of the research cohort study are to obtain detailed clinical phenotyping and immunological analysis of blood samples, aiming to identify and validate biomarkers of disease activity and response to treatment and prognostic markers.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
CountriesUnited Kingdom
CollaboratorsMedical Research Council, Imperial College Healthcare NHS Trust, University College, London, Queen Mary University of London, GlaxoSmithKline, University of Cambridge

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2010
Enrollment StartJan 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.5 years ago